Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03004248 · ClinicalTrials.gov registry record · Phase 3
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
A Phase 3 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,691
- Enrollment target
NCT03004248: Completed Phase 3 study, sponsored by Revance Therapeutics.
NCT03004248 is a Phase 3 study that has completed, run by Revance Therapeutics. The registered enrollment target is 2,691 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (249% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03004248, a Phase 3 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,691 participants
- Enrollment target
Study Summary
This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
Primary Outcome
Incidence rates based on the number and percentage of subjects treated within each cycle who report Adverse Events (AEs) at anytime following study treatment. Note that subjects could receive up to 3 consecutive treatments during the 36-week follow up period.
Interventions
- BIOLOGICAL Botulinum Toxins, Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,691 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2018-10-17 |
| Phase | Phase 3 |
What the finished NCT03004248 record still lists
NCT03004248 is an interventional study that assigns participants to a tested intervention. Its 2,691 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (249% higher).
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxins, Type A is the first listed.
NCT03004248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03004248 about?
NCT03004248 is a clinical study titled "Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines". This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.
What is the current status of trial NCT03004248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,691 participants. The study started on 2016-12-09. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT03004248?
The interventions under investigation include: Botulinum Toxins, Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03004248?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03004248's enrollment target sits among peer trials
2,691 84th of 2000 higher than 1,917 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05111925 · 2,690 participants
Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI